CAS 198821-22-6|merimepodib

Introduction：Basic information about CAS 198821-22-6|merimepodib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. merimepodib BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	merimepodib
CAS Number	198821-22-6	Molecular Weight	452.460
Density	1.4±0.1 g/cm3	Boiling Point	571.4±50.0 °C at 760 mmHg
Molecular Formula	C₂₃H₂₄N₄O₆	Melting Point	/
MSDS	/	Flash Point	299.4±30.1 °C

Names

Name	[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
Synonym	More Synonyms

merimepodib BiologicalActivity

Description	Merimepodib is a novel noncompetitive inhibitor of IMPDH (Inosine monophosphate dehydrogenase).
Related Catalog	Signaling Pathways >>Anti-infection >>HBVSignaling Pathways >>Anti-infection >>HCVResearch Areas >>Infection
In Vitro	VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal[1]. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine[2].
In Vivo	Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation[1]. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals[3].
Cell Assay	The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM l-glutamine. EMCV is infected at 500 PFU/107 L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof.
References	[1]. Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. [2]. Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66. [3]. Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Drugs Exp Clin Res. 2001;27(3):89-95.

Chemical & Physical Properties

Density	1.4±0.1 g/cm3
Boiling Point	571.4±50.0 °C at 760 mmHg
Molecular Formula	C₂₃H₂₄N₄O₆
Molecular Weight	452.460
Flash Point	299.4±30.1 °C
Exact Mass	452.169586
PSA	130.93000
LogP	2.05
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.632
InChIKey	JBPUGFODGPKTDW-SFHVURJKSA-N
SMILES	COc1cc(NC(=O)Nc2cccc(CNC(=O)OC3CCOC3)c2)ccc1-c1cnco1
Storage condition	2-8℃

Synonyms

MMPD

Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester

(3S)-Tetrahydro-3-furanyl [3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)benzyl]carbamate

Tyverb/Tykerb

Merimebodib

VX-497

merimepodib

Merimepodib (USAN/INN)

(3S)-tetrahydrofuran-3-yl [3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)benzyl]carbamate

Recommended......